BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia

被引：3
|
作者：
Hogdal, Leah [1 ]
Chyla, Brenda [2 ]
McKeegan, Evelyn [2 ]
Leverson, Joel [2 ]
Potluri, Jalaja [2 ]
Falotico, Nancy [2 ]
Ricker, Justin [2 ]
Humerickhouse, Rod [2 ]
Mabry, Mack [2 ]
Foight, Glenna [3 ]
Keating, Amy [3 ]
Galinsky, Ilene [1 ]
Stone, Richard [1 ]
DeAngelo, Daniel [1 ]
Konopleva, Marina [4 ]
Letai, Anthony [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Abbvie Inc, N Chicago, IL USA
[3] MIT, Cambridge, MA 02139 USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-2834
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2834
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)
    Konopleva, Marina
    Pollyea, Daniel A.
    Potluri, Jalaja
    Chyla, Brenda J.
    Busman, Todd
    McKeegan, Evelyn
    Salem, Ahmed
    Zhu, Ming
    Ricker, Justin L.
    Blum, William
    DiNardo, Courtney D.
    Dunbar, Martin
    Kirby, Rachel
    Falotico, Nancy
    Leverson, Joel D.
    Humerickhouse, Rod A.
    Mabry, Mack
    Stone, Richard M.
    Kantarjian, Hagop M.
    Letai, Anthony G.
    BLOOD, 2014, 124 (21)
  • [2] Correlative biomarkers of clinical activity of the BCL-2 inhibitor, venetoclax (ABT-199/GDC-0199), in acute myeloid leukemia patients
    Popovic, Relja
    Daver, Naval
    Ruvolo, Vivian
    Chen, Ken
    Wang, Zixing
    Huang, Xin
    Mabry, Mack
    Potluri, Jalaja
    McKeegan, Evelyn
    Konopleva, Marina
    Chyla, Brenda J.
    CANCER RESEARCH, 2016, 76
  • [3] Studying BCL-2 dependence using BH3 profiling in a phase 2 clinical trial of ABT-199 in acute myeloid leukemia.
    Hogdal, Leah
    Chyla, Brenda
    McKeegan, Evelyn
    Leverson, Joel
    Potluri, Jalaja
    Humerickhouse, Rod
    Mack, Mabry
    DeAngelo, Daniel
    Galinsky, Ilene
    Stone, Richard
    Letai, Anthony
    CLINICAL CANCER RESEARCH, 2015, 21
  • [4] Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models
    Han, Lina
    Zhang, Qi
    Shi, Ce
    Leverson, Joel
    Dail, Monique
    Phillips, Darren C.
    Chen, Jun
    Jin, Sha S.
    Jacamo, Rodrigo Omar
    Daver, Naval
    Jabbour, Elias J.
    Kantarjian, Hagop M.
    Andreeff, Michael
    Sampath, Deepak
    Konopleva, Marina
    BLOOD, 2015, 126 (23)
  • [5] Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models
    Han, Lina
    Zhang, Qi
    Shi, Ce
    Cavazos, Antonio
    Ruvolo, Vivian R.
    Leverson, Joel D.
    Dail, Monique
    Phillips, Darren C.
    Chen, Jun
    Jin, Sha S.
    Jacamo, Rodrigo
    Daver, Naval
    Jabbour, Elias
    Kantarjian, Hagop M.
    Andreeff, Michael
    Sampath, Deepak
    Konopleva, Marina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S282 - S282
  • [6] Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models
    Han, Lina
    Zhang, Qi
    Shi, Ce
    Cavazos, Antonio
    Ruvolo, Vivian
    Leverson, Joel
    Monique, Dail
    Phillips, Darren C.
    Chen, Jun
    Jin, Sha S.
    Jacamo, Rodrigo Omar
    Daver, Naval
    Jabbour, Elias J.
    Kantarjian, Hagop M.
    Andreeff, Michael
    Sampath, Deepak
    Konopleva, Marina
    BLOOD, 2016, 128 (22)
  • [7] Clinical proof of concept for the first-in-class BCL-2-selective inhibitor venetoclax (ABT-199/GDC-0199)
    Leverson, Joel D.
    CANCER RESEARCH, 2016, 76
  • [8] BCL-2-Selective BH3 Mimetic ABT-199 Is a Potent Agent For Acute Myeloid Leukemia
    Pan, Rongqing
    Debose, LaKeisha
    Benito, Juliana M.
    Golfman, Leonard S.
    Zweidler-McKay, Patrick A.
    Han, Lina
    Harutyunyan, Karine G.
    Mu, Hong
    Ruvolo, Vivian R.
    Park, Eugene
    Muschen, Markus
    Leverson, Joel
    Borthakur, Gautam
    Kantarjian, Hagop M.
    Ruvolo, Peter P.
    Andreeff, Michael
    Konopleva, Marina
    BLOOD, 2013, 122 (21)
  • [9] Dynamic BH3 Profiling Predicts for Clinical Response to Lenalidomide Plus Chemotherapy in Relapsed Acute Myeloid Leukemia
    Garcia, Jacqueline S.
    Bhatt, Shruti
    Fell, Geoffrey
    Blonquist, Traci M.
    Taw, Jack
    Iberri, David
    Letai, Anthony
    Medeiros, Bruno C.
    BLOOD, 2018, 132
  • [10] BH3 Profiling Predicts On-Target Cell Death Due To Selective Inhibition Of BCL-2 By ABT-199 In Acute Myelogenous Leukemia
    Hogdal, Leah
    DeAngelo, Daniel J.
    Stone, Richard M.
    Gaidzik, Verena I.
    Bucci, Donna
    Doehner, Konstanze
    Marcucci, Guido
    Ryan, Jeremy
    Letai, Anthony
    BLOOD, 2013, 122 (21)
12345